Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Incomplete clonal deletion as prerequisite for tissue-specific minor antigen tolerization
Nina Pilat, … , Fritz Wrba, Thomas Wekerle
Nina Pilat, … , Fritz Wrba, Thomas Wekerle
Published May 19, 2016
Citation Information: JCI Insight. 2016;1(7):e85911. https://doi.org/10.1172/jci.insight.85911.
View: Text | PDF
Research Article Immunology Transplantation

Incomplete clonal deletion as prerequisite for tissue-specific minor antigen tolerization

  • Text
  • PDF
Abstract

Central clonal deletion has been considered the critical factor responsible for the robust state of tolerance achieved by chimerism-based experimental protocols, but split-tolerance models and the clinical experience are calling this assumption into question. Although clone-size reduction through deletion has been shown to be universally required for achieving allotolerance, it remains undetermined whether it is sufficient by itself. Therapeutic Treg treatment induces chimerism and tolerance in a stringent murine BM transplantation model devoid of myelosuppressive recipient treatment. In contrast to irradiation chimeras, chronic rejection (CR) of skin and heart allografts in Treg chimeras was permanently prevented, even in the absence of complete clonal deletion of donor MHC-reactive T cells. We show that minor histocompatibility antigen mismatches account for CR in irradiation chimeras without global T cell depletion. Furthermore, we show that Treg therapy–induced tolerance prevents CR in a linked suppression–like fashion, which is maintained by active regulatory mechanisms involving recruitment of thymus-derived Tregs to the graft. These data suggest that highly efficient intrathymic and peripheral deletion of donor-reactive T cells for specificities expressed on hematopoietic cells preclude the expansion of donor-specific Tregs and, hence, do not allow for spreading of tolerance to minor specificities that are not expressed by donor BM.

Authors

Nina Pilat, Benedikt Mahr, Lukas Unger, Karin Hock, Christoph Schwarz, Andreas M. Farkas, Ulrike Baranyi, Fritz Wrba, Thomas Wekerle

×

Figure 3

Treg-treated mice maintain tolerance through regulatory mechanisms and confer infectious tolerance.

Options: View larger image (or click on image) Download as PowerPoint
Treg-treated mice maintain tolerance through regulatory mechanisms and c...
(A) Long-term tolerant mice were challenged with anti-CD25 mAb, anti-CTLA4 mAb, or anti-PD1 mAb 100 days after BMT to assess the impact of Tregs in long-term graft survival (control [n = 11] vs. anti-CD25 [n = 7], P = 0.0025; vs. anti-CTLA4 [n = 10], P = 0.0158; vs. anti-PD1 [n = 5], P < 0.0001; log-rank). Data are pooled from 2 independent experiments. (B) Surviving grafts of Treg chimeras were analyzed for signs of chronic rejection (CR; >50 days after treatment; ***P > 0.0001, Fisher’s exact test). (C) The longevity of therapeutically transferred (CD45.1 congenic) Tregs (n = 3/time point) was followed by flow cytometry in lymph nodes (LN) and spleen (SPL). (D and E) Chimeric mice conditioned with either 3-Gy or Treg-BMT protocols are challenged with skin grafts for tolerance assessment and infectious tolerance. (D) Mice received fully mismatched donor grafts (BALB/c) and donor grafts including an additional minor antigen mismatch (BALB/c-HY). Survival is shown for 3-Gy chimeras (3-Gy BALB/c, median survival time [MST] > 100 days, n = 5; 3-Gy BALB/c-HY, MST = 14 days, n = 3), Treg chimeras (Treg BALB/c, MST > 100 days, n = 10; Treg BALB/c-HY, MST = 33 days, n = 5), and naive mice (naive HY, MST = 24 days, n = 7). (E) Rejection kinetics for Phlp5 allergen as additional minor antigen are shown (3-Gy BALB/c, MST > 100 days, n = 5; 3-Gy BALB/c-Phlp5, MST = 9 days, n = 5; Treg BALB/c, MST > 80 days, n = 10; Treg BALB/c-Phlp5, MST = 14.5 days, n = 7; naive BALB/c-Phlp5, MST = 6 days, n = 5). Treg chimeras show prolonged survival vs. 3-Gy chimeras (P = 0.0046 for HY; P = 0.0118 for Phlp5) or naive mice (P = 0.0051 for HY; P = 0.0021 for Phlp5; all using log-rank). (F) The reactivity of sera (3 weeks after skin graft rejection) from 3-Gy chimeras (n = 5) and Treg chimeras (n = 6) with syngeneic (B6), donor (BALB/c), and BALB/c-Phlp5 thymocytes is shown by flow cytometry through indirect staining with anti–mouse IgG.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts